BioSpace News Archive

Highlight Therapeutics, a clinical-stage biopharmaceutical company developing RNA-based therapies against cancer, announces it has entered into a second Phase II trial collaboration with a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A., known as MSD outside the U.S. and Canada.

Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into an agreement with Abingdon Health for the manufacture of Avacta’s saliva-based rapid SARS-CoV-2 antigen test as part of its ongoing expansion of manufacturing capacity.

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, announced that it has received ethics approval to include Australian hospitals in the Phase 3 randomized controlled trial of remestemcel-L in ventilator-dependent COVID-19 patients with acute respiratory distress syndrome.

Promethera® Biosciences SA, a global innovator in cell-based medicines and liver diseases, based in Wallonia, Belgium, announced that John Tchelingerian, PhD, has resigned from his position as Chief Executive Officer and member of the Board of Directors, effective 27 August 2020.

Liam Kelly, Chairman, President and CEO, Teleflex Incorporated, is scheduled to speak at the Morgan Stanley 18th Annual Global Healthcare Conference on Wednesday, September 16, 2020 at 2:00 p.m..

National MENtion It® campaign examines how COVID-19 has affected men’s outlook on health and how they are coping with all of the changes

BiomX XMarker biomarker discovery platform to potentially inform Boehringer Ingelheim’s development of IBD therapeutics

Pivotal Studies for KEYTRUDA® (pembrolizumab) in Esophageal Cancer (KEYNOTE-590) and LYNPARZA® (olaparib) in Prostate Cancer (PROfound) Selected for ESMO Presidential Symposium Sessions

Central Ohio Urology Group, one of the largest urology practices in Central Ohio and the Columbus MSA, has acquired ExactVu™ Micro-Ultrasound, specifically designed to aid in the diagnosis of prostate cancer using real-time imaging for biopsy guidance.

Calithera Biosciences, Inc. announced that the compensation committee of the company’s board of directors granted one new employee a non-qualified stock option to purchase an aggregate of 8,000 shares of Calithera’s common stock, at a per share exercise price of $4.03 the closing trading price on August 31, 2020.